GPC1 and colorectal carcinoma: Statistical analysis of the SNA, AAL, and CA19‐9 antibody groups revealed that fucose was the only biomarker that significantly distinguished the presence of PCa in metastatic plasma samples (p < 0.0001, n = 3).[69, 70] The diagnostic potential of GPC1‐expressing exosomes was also validated using plasma samples from CRC patients.